3 Legacy Health Care Dividend Stocks That Never Go Out of Style
Johnson & Johnson (JNJ), Abbott Laboratories (ABT), and Medtronic (MDT) are highlighted for their long dividend growth streaks and steady demand in healthcare. JNJ, with a 64-year streak, aims for $100B revenue, yields 1.91%, and has a AAA credit rating. ABT, a Dividend Aristocrat, yields 2.28% and focuses on aging population growth. MDT offers the highest yield at 2.77% and the lowest forward multiple. All three cover payouts with adjusted earnings and free cash flow.
How this was made

The 30-second read
Why it matters
While each company raised its dividend, the increases are modest and largely expected, offering limited new trading opportunities.
Market read
The piece serves as a dividend‑focus overview for income investors, with minimal immediate market impact.
What to watch
Potential litigation costs at JNJ and the upcoming Abbott nutrition spinoff could offset dividend benefits.
Background
The article profiles three legacy health‑care companies—Johnson & Johnson, Abbott Laboratories, and Medtronic—highlighting their long dividend‑increase streaks and recent payout changes.
Ticker impact
Johnson & Johnson announced its 64th consecutive dividend increase, raising the quarterly payout to $1.34 and provided FY free cash flow guidance of $21 billion.
potential modest upside as the higher dividend supports valuation
The increase is incremental (3.1%) and aligns with the company's strong cash flow, offering limited upside pressure.
Abbott Laboratories reported a 54‑year dividend‑increase streak and disclosed a quarterly dividend of $0.63, with management indicating a future dividend increase.
limited upside as the dividend hike is expected and already priced in
The news reiterates an existing trend without new material catalyst, so price impact is likely muted.
Medtronic announced its 49th consecutive dividend increase, raising the quarterly payout to $0.72 and provided FY non‑GAAP EPS guidance of $5.94‑$6.00.
slight upside potential as the dividend raise reinforces income appeal
The increase is modest (one cent) and reflects ongoing cash‑flow strength, offering limited new price impetus.
Market effects
Reinforces the appeal of dividend‑focused health‑care stocks for income investors.
US‑listed health‑care dividend aristocrats may see modest buying pressure.
Limited; the story is US‑centric and does not affect broader markets.
Counterpoint
The incremental dividend hikes may not justify a price rally given modest growth and existing valuation.
Key entities
- companyJohnson & Johnson
US‑listed health‑care conglomerate with a 64‑year dividend streak.
- companyAbbott Laboratories
US‑listed medical‑device and diagnostics firm with a 54‑year dividend streak.
- companyMedtronic
US‑listed medical‑device maker with a 49‑year dividend streak.



